Onconox Inc. Establishes New Headquarters at Princeton Innovation Center BioLabs to Support Clinical-Stage Growth

Summary

Onconox Inc., a Princeton-based biotechnology company advancing precision oncology therapies, has relocated its corporate headquarters to Princeton Innovation Center BioLabs. The move places Onconox within one of New Jersey’s leading life sciences innovation hubs and supports the company’s transition into a clinical-stage biotech as it prepares to advance OCN001 into first-in-human studies in 2026.

Onconox Inc., a biotechnology company developing precision, low-burden therapies for oncology and other high-unmet-need indications, today announced the relocation of its corporate headquarters to Princeton Innovation Center BioLabs (PICB) in Princeton, New Jersey.

The move reflects Onconox’s progression into its next phase of growth as a clinical-stage biotech company and aligns with its strategic focus on capital efficiency, scientific excellence, and ecosystem engagement. The relocation is effective immediately.

Princeton Innovation Center BioLabs is a purpose-built life sciences incubator offering flexible laboratory and office space, shared scientific infrastructure, and access to a collaborative network of biotech entrepreneurs, academic innovators, and industry partners. The centre is widely recognised for supporting early- and clinical-stage life science companies through resource efficiency, mentorship, and proximity to key regional stakeholders.

By establishing its headquarters at PICB, Onconox gains access to scalable lab-ready infrastructure while remaining embedded in the Princeton and greater New Jersey life sciences ecosystem. This positioning supports the company’s ongoing IND-enabling activities and preparations to bring its lead programme, OCN001, into the clinic in 2026.

Geoff Muckle, Chief Executive Officer of Onconox Inc., commented:"Relocating our headquarters to Princeton Innovation Center BioLabs is a strategic step as Onconox transitions toward clinical execution. PICB offers an exceptional environment for biotech innovation, combining high-quality infrastructure with a collaborative ecosystem that supports both scientific progress and capital efficiency. Being based here strengthens our ability to attract talent, engage partners and investors, and execute our clinical and platform strategy with discipline."

The move also reinforces Onconox’s long-term commitment to New Jersey as a centre for biotechnology and pharmaceutical innovation. From its new headquarters, the company will continue to advance its precision-delivery programmes while building the operational foundations required for future clinical and corporate milestones.

Further updates will be shared as Onconox progresses through its clinical development roadmap.